A phase 2 randomized, double-blind, placebocontrolled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma Meeting Abstract
| Authors: | Krug, L.; di Pietro, A.; Narwal, R.; Robbins, P.; Fu, D.; Shalabi, A.; Ibrahim, R.; Calabro, L.; Kindler, H. |
| Abstract Title: | A phase 2 randomized, double-blind, placebocontrolled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma |
| Meeting Title: | 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 1 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2013 Nov 8-10 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2013-11-07 |
| Language: | English |
| DOI: | 10.1186/2051-1426-1-S1-P132 |
| PROVIDER: | manual |
| PMCID: | PMC3990330 |
| Notes: | Meeting Abstract: P132 |
Altmetric
Citation Impact
BMJ Impact Analytics